strategies for managing treatment-resistant depression

May 2006

New evidence will improve strategies for managing treatment-resistant depression. More than HALF of patients continue to have symptoms after initial treatment for depression.

Switching to a different antidepressant is helpful in about 25% of patients who don't respond to an SSRI.

Changing classes isn't always necessary. For example, patients who don't respond to citalopram (Celexa) are as likely to respond to sertraline (Zoloft) as they are to venlafaxine (Effexor XR) or bupropion (Wellbutrin SR).

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote